Overall, despite showing some degree of responses, with ORR ranging from 96% to 56% according to the different population of patients included in the studies, these trials confirmed an increased toxicity of pan-HDAC inhibitors, and vorinostat has, so far, not been approved for MM treatment. This evidence concerns the gene HDAC9 and Miyoshi myopathy.